What is it about?
We studied 384 people with transfusion-dependent beta-thalassaemia from 79 ethnic communities across Pakistan. We mapped beta-globin gene mutations, patient locations and response to low-dose thalidomide. Cd 8-9 (+G) was the most common mutation, followed by IVS 1-5, and response rates varied between regions.
Featured Image
Photo by Cassi Josh on Unsplash
Why is it important?
The results show that genetic variation and geography may influence treatment response. This could support more targeted testing and better-designed multicentre trials, helping researchers evaluate which patients are most likely to benefit while continuing to assess safety and effectiveness.
Perspectives
From my perspective, this work matters because The results show that genetic variation and geography may influence treatment response. I hope the findings support further research and informed, evidence-based decisions.
Yasar Yousafzai
Khyber Medical University
Read the Original
This page is a summary of: TRANSFUSION DEPENDENT β-THALASSEMIA PATIENTS TREATED WITH LOW-DOSE THALIDOMIDE, October 2023, Green Publication,
DOI: 10.53555/jptcp.v30i18.2997.
You can read the full text:
Contributors
The following have contributed to this page
